|
ÓÖÒ»Åúҽѧ¿ÆÑгÏÐ۸Àý±»Í¨±¨£¡À´Ô´£ü¿Æ¼¼½ÌÓý˾ ½üÈÕ£¬¿Æ¼¼½ÌÓý˾¹«²¼ÁË36Æðҽѧ¿ÆÑгÏÐ۸¼þµÄµ÷²é´¦Àí½á¹û¡£ÏÖ½«²¿·ÖÎÀÉú½¡¿µÐÐÕþ²¿ÃÅËùÊôÒ½ÁÆ»ú¹¹½üÆÚ¹«¿ªÍ¨±¨µÄҽѧ¿ÆÑгÏÐ۸¼þµ÷²é´¦Àí½á¹û×ªÔØÈçÏ£º Ò»¡¢Õã½Ê¡Á¢Í¬µÂÒ½Ôº¹ùÏþÁáΪͨѶ×÷Õß¡¢Õã½Ê¡Á¢Í¬µÂÒ½ÔºÖÜ·ïÈçΪ**×÷Õß¡¢ºþÖÝÊÐÖÐÐÄÒ½ÔºÅËÖÎÆ½Îª¹²Í¬**×÷Õß·¢±íµÄÂÛÎÄ¡°Long noncoding RNA DLX6-AS1 functions as a competing endogenous RNA for miR-577 to promote malignant development of colorectal cancer¡±£¬¾²é£¬Ïµ´æÔÚ±àÔìÑо¿¹ý³Ì¡¢Î¥·´¿ÆÑÐÂ×Àí¼°²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£ 1.Õã½Ê¡Á¢Í¬µÂÒ½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷Õß¹ùÏþÁ᣺ȡÏûÆäÖÐÎ÷Ò½½áºÏÖ÷ÖÎҽʦרҵ¼¼ÊõÖ°ÎñƸÈÎ,רҵ¼¼Êõ¸ÚλÓÉÊ®¼¶½µÆ¸ÎªÊ®Ò»¼¶£¬2ÄêÄÚ²»µÃ½úÉýרҵ¼¼ÊõÖ°Îñ¼°×¨Òµ¼¼Êõ¸ÚλµÈ¼¶,3ÄêÄÚÄê¶È¿¼ºË²»µÃÆÀΪÓÅÐãµÈ´Î£¬5ÄêÄÚ²»µÃÉ걨¸÷¼¶¸÷ÀàÈ˲š¢¿ÆÑÐÏîÄ¿£¬ÊÕ»ØÏà¹Ø¿ÆÑн±ÀøºÍ°æÃæ·Ñ£¬½ëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ £¨2£©¶Ô**×÷ÕßÖÜ·ïÈ磺רҵ¼¼Êõ¸ÚλÓɰ˼¶½µÆ¸Îª¾Å¼¶£¬2ÄêÄÚ²»µÃ½úÉýרҵ¼¼ÊõÖ°Îñ¼°×¨Òµ¼¼Êõ¸ÚλµÈ¼¶,³·Ïú2019ÄêÄê¶È¿¼ºËÓÅÐãµÈ´Î£¬3ÄêÄÚÄê¶È¿¼ºË²»µÃÆÀΪÓÅÐãµÈ´Î£¬5ÄêÄÚ²»µÃÉ걨¸÷¼¶¸÷ÀàÈ˲š¢¿ÆÑÐÏîÄ¿£¬ÊÕ»ØÏà¹Ø¿ÆÑн±ÀøºÍ°æÃæ·Ñ£¬ÔðÁî¼ì²é¡¢½ëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ £¨3£©¶ÔÆäËû×÷ÕßÉò·æ¡¢»ÆÂ·ÇÅ¡¢²Ìçæ£ºÈ¡ÏûÉ걨¸÷¼¶¸÷ÀàÈ˲š¢¿ÆÑÐÏîÄ¿×ʸñ1Ä꣬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ 2.ºþÖÝÊÐÖÐÐÄÒ½Ôº¶Ô¹²Í¬**×÷ÕßÅËÖÎÆ½×÷³öÈçÏ´¦Àí£ºÈ¡ÏûÉ걨¸÷Àà¸÷¼¶¿ÆÑÐÏîÄ¿×ʸñ1Äê¡£ ¶þ¡¢Õã½Ê¡º¼ÖÝÊкìÊ®×Ö»áÒ½ÔºÀî¿ÆÎªÍ¨Ñ¶×÷Õß¡¢ÍõΰΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Long non-coding RNA ROR1-AS1 induces tumorigenesis of colorectal cancer by affecting Wnt/¦Â-catenin signaling pathway¡±£¬¾²é£¬´æÔÚ´úд¡¢Êý¾ÝÔì¼ÙµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**×÷ÕßÍõΰ£ºÈ¡ÏûÉ걨ְ³Æ¡¢¸÷Àà¿ÆÑмƻ®ÏîÄ¿¡¢³É¹û½±Àø¡¢È˲ÅÏîÄ¿×ʸñ5Ä꣬ȡÏû½ü5Äê»ñµÃµÄÒ½ÔºÈÙÓþ£¬¿Û³ýÆä¼¨Ð§¹¤×Ê2¸öÔ£¬½µµÍ¸ÚλµÈ¼¶ÖÁרҵ¼¼ÊõÊ®¼¶£¬½«ÆäÎ¥¹æÊ§ÐÅÐÐΪ¼ÇÈëѧÊõ³ÏÐŵµ°¸£¬Í¨±¨ÅúÆÀ¡£ 2.¶ÔͨѶ×÷ÕßÀî¿Æ£ºÈ¡ÏûÉ걨ְ³Æ¡¢¸÷Àà¿ÆÑмƻ®ÏîÄ¿¡¢³É¹û½±Àø¡¢È˲ÅÏîÄ¿×ʸñ5Ä꣬ȡÏû½ü5Äê»ñµÃµÄÒ½ÔºÈÙÓþ£¬¿Û³ýÆä¼¨Ð§¹¤×Ê1¸öÔ£¬½«ÆäÎ¥¹æÊ§ÐÅÐÐΪ¼ÇÈëѧÊõ³ÏÐŵµ°¸£¬Í¨±¨ÅúÆÀ¡£ Èý¡¢Õã½Ê¡Äþ²¨ÊеھÅÒ½ÔººÎÑǹâΪͨѶ×÷Õß¡¢ÓàÐã¹úΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Long non-coding RNA PVT1 functions as an oncogene in human colon cancer through miR-30d-5p/RUNX2 axis¡±£¬¾²é£¬Ïµ´æÔÚÊý¾ÝÔì¼ÙµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦Àí£º 1.¶ÔͨѶ×÷ÕߺÎÑǹ⣺ȡÏûÉ걨¿Æ¼¼¼Æ»®£¨»ù½ð£©ÏîÄ¿¼°¿Æ¼¼±¨½±×ʸñ£¬µ£ÈÎÂÛÎÄ¡¢¿ÎÌâ¡¢»ù½ð¡¢±¨½±µÈÆÀÉóר¼Ò×ʸñ5Äꣻ¿ÆÑгÏÐŽëÃã̸»°¼°ÊéÃæ¼ì²é£»¿Û·£¼¨Ð§¹¤×Ê3¸öÔ£»È¡Ïûµ±ÄêÆÀÏÈÆÀÓÅ×ʸñ£»Í¨±¨ÅúÆÀ¡£ 2.¶Ô**×÷ÕßÓàÐã¹ú£ºÈ¡ÏûÖ°³ÆÖ°Îñ½úÉý×ʸñ3ÄꣻȡÏûÉ걨¿Æ¼¼¼Æ»®£¨»ù½ð£©ÏîÄ¿¼°¿Æ¼¼±¨½±×ʸñ£¬µ£ÈÎÂÛÎÄ¡¢¿ÎÌâ¡¢»ù½ð¡¢±¨½±µÈÆÀÉóר¼Ò×ʸñ5Äꣻ¿ÆÑгÏÐŽëÃã̸»°¼°ÊéÃæ¼ì²é£»¿Û·£¼¨Ð§¹¤×Ê3¸öÔ£»ÊջذæÃæ·Ñ±¨ÏúºÍ¿ÆÑн±Àø£»È¡Ïûµ±ÄêÆÀÏÈÆÀÓÅ×ʸñ£»Í¨±¨ÅúÆÀ¡£ ËÄ¡¢É½¶«Ê¡µÂÖÝÊÐÈËÃñÒ½ÔºÕÅޱޱΪ**¼æÍ¨Ñ¶×÷Õß·¢±íµÄÂÛÎÄ¡°Long non-coding RNA-ROR aggravates myocardialischemia/reperfusion injury¡±¡£¾²é£¬Ïµ´æÔÚÂòÂôÂÛÎĵÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶Ô**¼æÍ¨Ñ¶×÷ÕßÕÅÞ±Þ±£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬¹«¿ªÍ¨±¨ÅúÆÀ£¬È¡Ïû½úÉýÖ°ÎñÖ°³Æ¡¢É걨¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿µÈ×ʸñ5Ä꣬¼ÇÈë¿ÆÑгÏÐÅÐÅϢϵͳ¡£ 2.¶ÔµÚ¶þ×÷ÕßÀîÓ¨¡¢µÚÈý×÷ÕßÍõÅô£º¿ÆÑгÏÐŽëÃã̸»°£¬È¡Ïû½úÉýÖ°ÎñÖ°³Æ¡¢É걨¿Æ¼¼¼Æ»®£¨×¨Ïî¡¢»ù½ðµÈ£©ÏîÄ¿µÈ×ʸñ1Äê¡£ Î塢ɽ¶«Ê¡ÁÙÒÊÊÐÈËÃñÒ½ÔºÕŽ¨»ªÎª**×÷Õߣ¬ÁÙÒÊÊÐÈËÃñÒ½ÔºÕÔ·æ¡¢ÁÙÒÊÊÐÀ¼ÁêÏØÈËÃñÒ½ÔºÀîÓñ¹úΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°Curcumin Inhibits Proliferation and Soluble Collagen Synthesis of NIH/3T3 Cell Line by Modulation of miR-29a and via ERK1/2 and¦Â-catenin Pathways¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ÁÙÒÊÊÐÈËÃñÒ½Ôº¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º £¨1£©¶Ô**×÷ÕßÕŽ¨»ª£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å;¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ £¨2£©¶ÔͨѶ×÷ÕßÕԷ棺¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å;¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ £¨3£©¶ÔÆäËû×÷ÕßËÎ÷¡¢Àîά·å£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äê¡£ 2.ÁÙÒÊÊÐÀ¼ÁêÏØÈËÃñÒ½Ôº¶ÔͨѶ×÷ÕßÀîÓñ¹ú£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬È¡Ïû2020Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£ Áù¡¢É½¶«Ê¡ÁÙÒÊÊÐÈËÃñÒ½ÔºÕÔ¾üΪ**×÷Õß¡¢ÕžêÃÀΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°Salidroside Mitigates Hydrogen Peroxide-Induced Injury by Enhancement of microRNA-27a in Human Trabecular Meshwork Cells¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂô£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º 1.¶Ô**×÷ÕßÕÔ¾ü£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å;¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ 2.¶ÔͨѶ×÷ÕßÕžêÃÀ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å;¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ Æß¡¢É½¶«Ê¡ÁÙÒÊÊÐÖÐÐÄҽԺѦ·½Ï²Îª**×÷Õß¡¢Ìï·åΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°Neferine inhibits growth and migration of gastrointestinal stromal tumor cell line GIST-T1 by up-regulation of miR-449a¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º 1.¶Ô**×÷ÕßѦ·½Ï²£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ 2.¶ÔͨѶ×÷ÕßÌï·å£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äꣻ³·¸å¡£ 3.¶ÔÆäËû×÷ÕßÁõÕ×ϼ¡¢Ð콨¡¢ÐìÏþ¹â¡¢³ÂÐËÌ¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ °Ë¡¢É½¶«Ê¡ÁÙÒÊÊÐÖÐÐÄÒ½Ôº³Ì×ÓÃ÷Ϊ**×÷Õß¡¢ºîÊËÕñΪͨѶ×÷Õß·¢±íÂÛÎÄ¡°K-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3K18ac through the MDM2-GCN5-SIRT7 axis¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º 1.¶Ô**×÷Õß³Ì×ÓÃ÷£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä6ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ6Äꣻ³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ 2.¶ÔͨѶ×÷ÕߺîÊËÕñ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä1ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äꣻ³·¸å¡£ 3.¶ÔÆäËû×÷ÕßÀîÐã·å¡¢ÎäÓñ±ø¡¢ËïÒã¡¢Áõ±ù£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ ¾Å¡¢É½¶«Ê¡ÁÙÒÊÊи¾Ó×±£½¡ÔºÀî»ÛΪͨѶ×÷Õß¡¢ÁÙÒÊÊÐÈËÃñҽԺѦÓÀÕäΪ**×÷Õß·¢±íÂÛÎÄ¡°Angelica polysaccharide moderates hypoxia-evoked apoptosis and autophagy in rat neural stem cells by downregulation of BNIP3¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇéͬÒâ¡£ 1.ÁÙÒÊÊи¾Ó×±£½¡Ôº¶ÔͨѶ×÷ÕßÀî»Û×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»È¡ÏûÆä5ÄêÄÚÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ£»³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ 2.ÁÙÒÊÊÐÈËÃñÒ½Ôº¶Ô**×÷ÕßѦÓÀÕä×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·ÏúÆäÀûÓÿÆÑÐʧÐÅÐÐΪƸÈεĸ±Ö÷ÈÎҽʦ×ʸñ£»³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ 3.ɽ¶«Ê¡ÃºÌ¿ÁÙÒÊÎÂȪÁÆÑøÔº¶ÔÆäËû×÷ÕßÀ÷×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·ÏúÆäÀûÓÿÆÑÐʧÐÅÐÐΪ»ñµÃ¸±Ö÷ÈÎҽʦ×ʸñ£»³·¸å¡£ Ê®¡¢É½¶«Ê¡ÁÙÒÊÊÐÀ¼ÁêÏØÈËÃñÒ½ÔºÐÁÀöºìΪ**¼æÍ¨Ñ¶×÷Õß·¢±íÂÛÎÄ¡°Overexpression of DJ-1 expressionprotects cardiomyocyte apoptosis inducedby ischemia reperfusion¡±£¬¾²é£¬Ïµ´æÔÚÂÛÎÄÂòÂôÐÐΪ£¬ÇÒͶ¸åǰδ°´¹æ·¶³ÌÐò»ñµÃ**×÷ÕßÖªÇéͬÒâ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦ÀíÈçÏ£º 1.¶Ô**¼æÍ¨Ñ¶×÷ÕßÐÁÀöºì£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡ÏûÆä²Î¼Ó2020Äê¶ÈÆÀÏÈÊ÷ÓÅ£¬Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡ÏûÆä5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡ÏûÆä5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ³·¸å£»¿Û·£¼¨Ð§¹¤×Ê5000Ôª¡£ 2.¶ÔÆäËû×÷ÕßÁõÎľü¡¢ËÎÌΡ¢ÕÅÁÕ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»È¡Ïû2020Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£ ʮһ¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÀî·åΪͨѶ×÷Õß¡¢ÍõΰΰΪ**×÷Õß¡¢ºÂÑÒΪ²¢ÁÐ**×÷Õß·¢±íµÄÂÛÎÄ¡°Notoginsenoside R1 alleviates high glucose-evoked damage in RSC96 cells through down-regulation of miR-503¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³ÌµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÀî·å£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬Ôð³É¾¡¿ìÁªÏµÔÓÖ¾Éç³·¸å£¬µ³ÄÚ¾¯¸æ¡£ 2.¶Ô**×÷ÕßÍõΰΰ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£ 3.¶Ô²¢ÁÐ**×÷ÕߺÂÑÒ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£ Ê®¶þ¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÐí·ÉΪͨѶ×÷Õߣ¬×£°®¶«Îª**×÷Õߣ¬ËïÓ¯Ó¯¡¢ÂíÇï¾ÕΪ²¢ÁÐ**×÷Õß·¢±íµÄÂÛÎÄ¡°lncRNA©ATB promotes viability,migration,and angiogenesis in human microvascular endothelial cells by sponging microRNA©195¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³ÌµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÐí·É£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£ 2.¶Ô**×÷Õß×£°®¶«£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£ 3.¶Ô²¢ÁÐ**×÷ÕßËïÓ¯Ó¯¡¢ÂíÇï¾Õ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ Ê®Èý¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÕÔÑåÄþΪͨѶ×÷Õß¡¢ÆëÓñçôΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°CBP© riggered KDM2B acetylation accelerates the carcinogenesis of colon cancer¡±£¬¾²é£¬Ïµ´æÔÚ´úдµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÕÔÑåÄþ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£»È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£ 2.¶Ô**×÷Õ߯ëÓñçô£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬»º½ú3Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬ÐÐÕþ¾¯¸æ¡£ Ê®ËÄ¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½Ôº¿×µÂæ·ÎªÍ¨Ñ¶×÷Õß¡¢·¿ÀÚΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Icariin inhibits cell proliferation,migration and invasion by down-regulation of microRNA-625-3p in thyroid cancer cells¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾ÝµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷Õß¿×µÂæ·£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ¡£ 2.¶Ô**×÷Õß·¿ÀÚ£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£ 3.¶Ô²ÎÓë×÷ÕßÐìç⣺ȡÏû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£ Ê®Î塢ɽ¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÑÕÍ¢ÕñΪͨѶ×÷Õß¡¢ÒÁ¹ãÀ¤Îª**×÷Õß·¢±íµÄÂÛÎÄ¡°Ginsenoside Rg1 defenses PC-12 cells against hydrogen peroxide-caused damage via up-regulation of miR-216a-5p¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÑÕÍ¢Õñ£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£ 2.¶Ô**×÷ÕßÒÁ¹ãÀ¤£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£ Ê®Áù¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÐìÏ×Â×Ϊ**¼æÍ¨Ñ¶×÷Õß·¢±íµÄÂÛÎÄ¡°Ras-PI3K pathway promotes osteosarcoma progression via regulating VRK1-mediated H2A phosphorylation at threonine 120¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶Ô**¼æÍ¨Ñ¶×÷ÕßÐìÏ×Â×£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ¡£ 2.¶Ô²ÎÓë×÷ÕßÓںƣº¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ Ê®Æß¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÍõÐñΪͨѶ×÷Õß¡¢ÇØÎ¯Î¯Îª**×÷Õß·¢±íµÄÂÛÎÄ¡°Inhibiting lncRNA ROR suppresses growth,migration and angiogenesis in microvascular endothelial cells by up-regulating miR-26¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢²»µ±ÊðÃûµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÍõÐñ£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»ºÆ¸2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£ 2.¶Ô**×÷ÕßÇØÎ¯Î¯£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬ÊÕ»ØÂÛÎÄ¿ÆÑн±ÀøºÍÈÙÓþ³ÆºÅ£¬»ºÆ¸2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£ 3.¶Ô²ÎÓë×÷ÕßÀîÏþÑÞ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ Ê®°Ë¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÃϽàΪͨѶ×÷Õß¡¢ÁõÐãϼΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Tanshinone IIA ameliorates lipopolysaccharide-induced inflammatory response in bronchial epithelium cell line BEAS-2B by down-regulating miR-27a¡±£¬¾²é£¬Ïµ´æÔÚ´Û¸ÄÊý¾Ý¡¢±àÔìÑо¿¹ý³Ì¡¢´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÃϽࣺȡÏû7ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû7Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú3Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ£¬Ãâ³ý¸±»¤Ê¿³¤Ö°Îñ¡£ 2.¶Ô**×÷ÕßÁõÐãϼ£ºÈ¡Ïû8ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû8Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬×·»Ø×÷Õ߸öÈËËùµÃµÄÂÛÎÄ¿ÆÑн±ÀøºÍÈÙÓþ³ÆºÅ£¬³·ÏúÒÑÈ¡µÃµÄ¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£»»º½ú5Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ£¬Ãâ³ý¸±»¤Ê¿³¤Ö°Îñ¡£ Ê®¾Å¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÕÅÏþ·ÒΪͨѶ×÷Õߣ¬ÕŹú²ý¡¢µÔéªÎª¹²Í¬**×÷Õß·¢±íµÄÂÛÎÄ¡°Alkannin represses growth of pancreatic cancer cells based on the down regulation of miR©199a¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÕÅÏþ·Ò£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬³·¸å£¬µ³ÄÚ¾¯¸æ¡£ 2.¶Ô**×÷ÕßÕŹú²ý£ºÈ¡Ïû5ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú1Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬µ³ÄÚ¾¯¸æ¡£ 3.¶Ô²¢ÁÐ**×÷ÕßµÔ骣º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ¡£ ¶þÊ®¡¢É½¶«Ê¡¼ÃÄþÊÐ**ÈËÃñÒ½ÔºÆëÓñçôΪͨѶ×÷Õß¡¢Àî½ðÁ¼Îª**×÷Õß·¢±íµÄÂÛÎÄ¡°Ginsenoside Rg3 inhibits cell growth,migration and invasion in Caco-2 cells by downregulation of lncRNA CCAT1¡±£¬¾²é£¬Ïµ´æÔÚ´úдµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷Õ߯ëÓñçô£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬»º½ú3Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬³·¸å£¬ÐÐÕþ¾¯¸æ¡£ 2.¶Ô**×÷ÕßÀî½ðÁ¼£ºÈ¡Ïû6ÄêÄÚ¿ÆÑÐÏîÄ¿¡¢¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£¬È¡Ïû6Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬È¡ÏûÆäÒÑ»ñµÃµÄѧ»á¡¢Ð»áµÈѧÊõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±×ʸñ£¬»º½ú2Äê¸ßÒ»¼¶×¨Òµ¼¼ÊõÖ°Îñ£¬ÐÐÕþ¾¯¸æ¡£ ¶þʮһ¡¢É½¶«Ê¡¼ÃÄÏÊÐÖÐÐÄҽԺʯѧ·åΪͨѶ×÷Õß¡¢ºÊÔóÊÐÁ¢Ò½ÔºÓÚ´¨¶«Îª**×÷Õß·¢±íµÄÂÛÎÄ¡°Long noncoding RNA CHRF exacerbates IL©6©induced inflammatory damages by downregulating microRNA©146a in ATDC5 cells¡±£¬¾²é£¬Ïµ´æÔÚʵÑéͼƬ´Û¸ÄµÄѧÊõ²»¶ËÐÐΪ¡£ 1.¼ÃÄÏÊÐÖÐÐÄÒ½Ôº¶ÔͨѶ×÷Õßʯѧ·å×÷³öÈçÏ´¦Àí£ºÔð³É³·¸å¡¢¿ÆÑгÏÐŽëÃã̸»°¡¢ÊÕ»ØÂÛÎÄ·¢±íÒѱ¨ÏúµÄÏà¹Ø·ÑÓúͽ±Àø×ʽð¡¢È¡Ïû5ÄêÄÚÖ°³ÆÆ¸ÈÎ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷Àà¿ÆÑн±Àø×ʸñ¡¢È¡Ïû5ÄêÉ걨¸÷ÀàÏÞÏî¿ÆÑÐÏîÄ¿µÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷¼¶¿Æ¼¼È˲ŵÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨Ñо¿Éúµ¼Ê¦×ʸñ¡£ 2.ºÊÔóÊÐÁ¢Ò½Ôº¶Ô**×÷ÕßÓÚ´¨¶«×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°¡¢Í¨±¨ÅúÆÀ¡¢Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£ ¶þÊ®¶þ¡¢É½¶«Ê¡¼ÃÄÏÊÐÖÐÐÄÒ½Ôº¼ÖÌúêΪͨѶ×÷Õß¡¢±õÖÝҽѧԺ¸½ÊôÒ½ÔºÍõÕ×ÁÖΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°long noncoding RNA maternally expressed gene 3 knockdown alleviates lipopolysaccharide-induced inflammatory injury by up-miR-203 in ATDCS cells¡±£¬¾²é£¬Ïµ´æÔÚʵÑéͼƬ´Û¸ÄµÄѧÊõ²»¶ËÐÐΪ¡£ 1.¼ÃÄÏÊÐÖÐÐÄÒ½Ôº¶ÔͨѶ×÷Õß¼ÖÌúê×÷³öÈçÏ´¦Àí£ºÔð³É³·¸å¡¢¿ÆÑгÏÐŽëÃã̸»°¡¢ÊÕ»ØÉæÏÓÂÛÎÄ·¢±íÒѱ¨ÏúµÄÏà¹Ø·ÑÓúͽ±Àø×ʽð¡¢È¡Ïû5ÄêÄÚÉ걨¸÷Àà¿ÆÑн±Àø×ʸñ¡¢È¡Ïû5ÄêÉ걨¸÷ÀàÏÞÏî¿ÆÑÐÏîÄ¿µÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷¼¶¿Æ¼¼È˲ŵÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÑо¿Éúµ¼Ê¦ÕÐÉú×ʸñ¡£ 2.±õÖÝҽѧԺ¸½ÊôÒ½Ôº¶Ô**×÷ÕßÍõÕ×ÁÖ×÷³öÈçÏ´¦Àí£ºÈ¡ÏûÆäÉêÇ벩ʿѧλ×ʸñ¡£ ¶þÊ®Èý¡¢É½¶«Ê¡¼ÃÄÏÊÐÖÐÐÄÒ½ÔºÕÅÇì¹úΪͨѶ×÷Õß¡¢ÁõÊçºãΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°green tea polyphenols protect PC12 cells against H2O2-induced damages by upregulating IncRNA MALATI¡±£¬¾²é£¬ÏµÎªÍ¨Ñ¶×÷Õß´Û¸ÄʵÑéͼƬµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÕÅÇì¹ú£ºÔð³É³·¸å¡¢¿ÆÑгÏÐŽëÃã̸»°¡¢ÊÕ»ØÉæÏÓÂÛÎÄ·¢±íÒѱ¨ÏúµÄÏà¹Ø·ÑÓúͽ±Àø×ʽð¡¢È¡Ïû5ÄêÄÚÉ걨¸÷Àà¿ÆÑн±Àø×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷ÀàÏÞÏî¿ÆÑÐÏîÄ¿µÄ×ʸñ¡¢È¡Ïû5ÄêÄÚÉ걨¸÷¼¶¿Æ¼¼È˲ŵÄ×ʸñ¡£ 2.¶Ô**×÷ÕßÁõÊçºã£º½ëÃã̸»°¡£ ¶þÊ®ËÄ¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºËïÐÂÑÒΪͨѶ×÷Õß¡¢Û²³ÇÏØÈËÃñҽԺǮµÀÁÖΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Notoginsenoside R1 protects WI-38 cells against lipopolysaccharide-triggered injury via adjusting miR-181a/TLR4 axis¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ºÊÔóÊÐÁ¢Ò½ÔºÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷ÕßËïÐÂÑÒ£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£ £¨2£©¶ÔÆäËû×÷ÕßÉÛÏÍÀ¤£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£ 2.Û²³ÇÏØÈËÃñÒ½Ôº¶Ô**×÷ÕßÇ®µÀÁÖ×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£ 3.ºÊÔóÊеÚÈýÈËÃñÒ½ÔºÆäËû×÷ÕßÀîÓ´º×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬1ÄêÄÚÈ¡ÏûÉêÇë»òÉ걨¿ÆÑмƻ®ÏîÄ¿×ʸñ¡£ ¶þÊ®Î塢ɽ¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºÑî´ºÇäΪͨѶ×÷Õß¡¢Û²³ÇÏØÈËÃñÒ½ÔºËΰ®Æ½Îª**×÷Õß·¢±íµÄÂÛÎÄ¡°Long noncoding RNA Alu©mediated p21 transcr1ptional regulator promotes proliferation,migration,and pipe-formation of human microvascular endothelial cells by sponging miR©126¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷ÕßÑî´ºÇ䣺³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£ £¨2£©¶ÔÆäËû×÷Õß·ëÈߣº¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£ 2.Û²³ÇÏØÈËÃñÒ½Ôº¶Ô**×÷ÕßËΰ®Æ½×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£ ¶þÊ®Áù¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºÍõ½ðÁúΪͨѶ×÷Õß¡¢ÌÆÊØÒåΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Long noncoding RNA MEG3 deteriorates inflammatory damage by downregulating microRNA-101a¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷ÕßÍõ½ðÁú£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£ 2.¶Ô**×÷ÕßÌÆÊØÒå¡¢ÆäËû×÷Õߺ«¾ýϼ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл4Äê¡£ 3.¶ÔÆäËû×÷Õß½¹»Û¡¢ÁõÓ±Ó±£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£ 4.¶ÔÆäËû×÷Õß˾æºÄÈ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл6Äê¡£ ¶þÊ®Æß¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½Ôº¿µ¾²ÎªÍ¨Ñ¶×÷Õß¡¢ÁõӱΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°Circular RNA ACR relieves high glucose©aroused RSC96 cell apoptosis and autophagy via declining microRNA-145-3p¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷Õß¿µ¾²£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£ £¨2£©¶Ô**×÷ÕßÁõÓ±£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£ £¨3£©¶ÔÆäËû×÷Õß³ÂÏþÇ죺¿ÆÑгÏÐŽëÃã̸»°£¬ÔÚͨ±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл1Äê¡£ 2.ºÊÔóÊд«È¾²¡Ò½Ôº¶ÔÆäËû×÷ÕßÒ¦¾§¾§×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹¿ÆÑл1Ä꣬1ÄêÄÚÈ¡ÏûÉêÇë»òÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍÍÆ³Ù1Äêרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ¡£ ¶þÊ®°Ë¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºË¾æºÄÈΪͨѶ×÷Õߣ¬ÁijÇÊÐÈËÃñÒ½ÔºÕÅÑ©ËÉ¡¢¶»ªÎ°Îª¹²Í¬**×÷Õß·¢±íµÄÂÛÎÄ¡°Tetramethylpyrazine partially relieves hypoxia-caused Damage of cardiomyocytes H9C2 by downregulation of mir-449a¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷Õß˾æºÄÈ£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл6Äê¡£ £¨2£©¶ÔÆäËû×÷Õߺ«¾ýϼ¡¢ÌÆÊØÒ壺¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл4Äê¡£ 2.ÁijÇÊÐÈËÃñÒ½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶Ô**×÷ÕßÕÅÑ©ËÉ£º¿ÆÑгÏÐŽëÃã̸»°£¬5ÄêÄÚÈ¡Ïûרҵ¼¼ÊõÖ°ÎñÉ걨ºÍƸÈÎ×ʸñ£¬5ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£¬5ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬¼ÇÈë¿ÆÑгÏÐÅʧÐŵµ°¸¡£ £¨2£©¶Ô**×÷Õß¶»ªÎ°£º¿ÆÑгÏÐŽëÃã̸»°£»½µ¼¶£¬´Ó¸±Ö÷ÈÎҽʦ½µÎªÖ÷ÖÎҽʦ£»³·Ïú»ñµÃµÄ¸±Ö÷ÈÎҽʦְ³Æ£¬3ÄêÄÚÈ¡Ïûרҵ¼¼ÊõÖ°ÎñÉ걨ºÍƸÈÎ×ʸñ£»3ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺÅ×ʸñ£»3ÄêÄÚÈ¡Ïû×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»¼ÇÈë¿ÆÑгÏÐÅʧÐŵµ°¸¡£ £¨3£©¶ÔÆäËû×÷ÕßÁõÓ£º1ÄêÄÚÈ¡ÏûÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺźÍרҵ¼¼ÊõÖ°Îñ½úÉýµÈ×ʸñ¡£ ¶þÊ®¾Å¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½ÔºÕÔº£ÍúΪͨѶ×÷Õß¡¢Û²³ÇÏØÈËÃñÒ½Ôº¸ßÏÍÈñΪ**×÷Õß·¢±íµÄÂÛÎÄ¡°K-Ras-PI3K regulates H3K56ac through PCAF to elevate the occurrence and growth of liver cancer¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷ÕßÕÔº£Íú£º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл5Äê¡£ £¨2£©¶ÔÆäËû×÷Õß³ÌÕ×Á¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл1Äê¡£ £¨3£©¶ÔÆäËû×÷ÕßÔ¬º£·æ£º¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл6Äê¡£ 2.Û²³ÇÏØÈËÃñÒ½Ôº¶Ô**×÷Õ߸ßÏÍÈñ×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£ ÈýÊ®¡¢É½¶«Ê¡ºÊÔóÊÐÁ¢Ò½Ôº¸¶Ô£ÎªÍ¨Ñ¶×÷Õß¡¢Û²³ÇÏØÈËÃñÒ½ÔºÕŽ¨»ªÎª**×÷Õß·¢±íµÄÂÛÎÄ¡°HOTAIR regulates lipopolysaccharide©induced inflammatory response in hepatocytes¡±£¬¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ºÊÔóÊÐÁ¢Ò½Ôº¶ÔÏà¹ØÔðÈÎÈË×÷³öÈçÏ´¦Àí£º £¨1£©¶ÔͨѶ×÷Õ߸¶Ô££º³·¸å£¬¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£ £¨2£©¶ÔÆäËû×÷Õß³Âíµ¡¢µÔÓñÑࣺ¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£¬Í£Ö¹²ÆÕþ×ÊÖú¿ÆÑÐÏîÄ¿ºÍ¿ÆÑл3Äê¡£ 2.Û²³ÇÏØÈËÃñÒ½Ôº¶Ô**×÷ÕßÕŽ¨»ª×÷³öÈçÏ´¦Àí£º¿ÆÑгÏÐŽëÃã̸»°£»Í¨±¨ÅúÆÀ£»È¡Ïû²Î¼Ó2021Äê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ£¬±¾Äê¶È¿¼ºË²»µÃÈ·¶¨ÎªÓÅÐãµÈ´Î£»È¡Ïû5ÄêÄڿƼ¼¼Æ»®ÏîÄ¿É걨×ʸñ¡£ Èýʮһ¡¢É½¶«Ê¡×Ͳ©ÊÐÁÙ×ÍÇøÈËÃñÒ½ÔºÍõÌÎΪͨѶ×÷Õß¡¢×Ͳ©ÊÐÖÐÐÄÒ½ÔºÉлªÎª**×÷Õß·¢±íµÄÂÛÎÄ¡°Over-expression of DJ-1 attenuates effects of curcumin on colorectal cancer cell proliferation and apotisis¡±¡£¾²é£¬Ïµ´æÔÚ´úд²¢·¢±íµÄѧÊõ²»¶ËÐÐΪ¡£ 1.ͨѶ×÷ÕßÍõÌÎÂÛÎÄ·¢±íʱ¾ÍÖ°ÓÚÁÙ×ÍÇøÈËÃñÒ½Ôº£¬ÏÖ¾ÍÖ°ÓÚ×Ͳ©ÊÐÖÐÐÄÒ½Ôº¡£ÁÙ×ÍÇøÈËÃñÒ½ÔººÍ×Ͳ©ÊÐÖÐÐÄÒ½Ôº¶ÔÍõÌÎ×÷³öÈçÏ´¦Àí£º³·¸å£¬ÊÕ»ØÂÛÎĽ±½ð½±Àø£¬5ÄêÄÚ²»µÃÉ걨ʡ¼¶**¿ÆÑпÎÌâºÍ¿ÆÑгɹû½±Àø£¬È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£¬ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Ä꣬»ºÆ¸1Ä꣬ȡÏûÄê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£ 2.×Ͳ©ÊÐÖÐÐÄÒ½Ôº¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³ö´¦Àí£º £¨1£©¶Ô**×÷ÕßÉлª£ºÈ¡Ïû5ÄêÄÚÊ¡¼¶¡¢**¿ÆÑÐÏîÄ¿¼°¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡Ïû5Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ5Äꣻ¿ÆÑгÏÐŽëÃã̸»°´¦£¬Í¨±¨ÅúÆÀ£»»ºÆ¸1ÄꣻȡÏûÄê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£ £¨2£©¶ÔÆäËû×÷ÕßÀîÃô¡¢ÂÞÓ¨¡¢»ÆÀ¤Ã÷£ºÈ¡Ïû3ÄêÄÚÊ¡¼¶¡¢**¿ÆÑÐÏîÄ¿¼°¿ÆÑн±Àø¡¢¿Æ¼¼³É¹û¡¢¿Æ¼¼È˲żƻ®µÈÉ걨×ʸñ£»È¡Ïû3Äê×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÔÝÍ£ÆäÑо¿Éúµ¼Ê¦ÉêÇë×ʸñ1Äꣻ¿ÆÑгÏÐŽëÃã̸»°£¬Í¨±¨ÅúÆÀ£»»ºÆ¸1ÄꣻȡÏûÄê¶ÈÆÀÏÈÊ÷ÓÅ×ʸñ¡£ ÈýÊ®¶þ¡¢É½¶«Ê¡±õÖÝÊÐÈËÃñÒ½Ôº¸¶ÑÞΪͨѶ×÷Õß¡¢±ÏÒæÃ÷Ϊ**×÷Õß·¢±íµÄÂÛÎÄ¡°Schizandrin A exerts anti-tumor effects on A375 cells by down-regulating H19¡±¡£¾²é£¬Ïµ´æÔÚ´úд´úͶµÄѧÊõ²»¶ËÐÐΪ¡£¶ÔÏà¹ØÔðÈÎÈËÔ±×÷³öÈçÏ´¦Àí£º 1.¶ÔͨѶ×÷Õ߸¶ÑÞ¡¢**×÷Õß±ÏÒæÃ÷£º¿ÆÑгÏÐŽëÃã̸»°£»È¡Ïû5ÄêÄÚÉêÇëºÍÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺš¢×¨Òµ¼¼ÊõÖ°Îñ½úÉýÒÔ¼°Ñ§Êõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±µÈ×ʸñ£¬È¡Ïû5ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ£»ÐÐÕþ¾¯¸æ£»³·¸å¡£ 2.¶ÔÆäËû×÷ÕßÍõÊçÑà¡¢³ÂÐËÐã¡¢²ÌСƼ£º¿ÆÑгÏÐŽëÃã̸»°£»È¡Ïû1ÄêÄÚÉêÇëºÍÉ걨¿Æ¼¼¼Æ»®ÏîÄ¿£¨×¨Ïî¡¢»ù½ðµÈ£©¡¢¿Æ¼¼½±Àø¡¢¿Æ¼¼È˲ųƺš¢×¨Òµ¼¼ÊõÖ°Îñ½úÉýÒÔ¼°Ñ§Êõ¹¤×÷»ú¹¹µÄίԱ»ò³ÉÔ±µÈ×ʸñ£¬È¡Ïû1ÄêÄÚ×÷ΪÌáÃû»òÍÆ¼öÈË¡¢±»ÌáÃû»òÍÆ¼öÈË¡¢ÆÀÉóר¼ÒµÈ×ʸñ¡£ END ±à¼£ºÐ¡»Æ |